GlassScriptPhysician profile
Mukarram Amine
NPI 1558899153
$2,428.38
in general payments reported to CMS, 2019-2025
21 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $729 · 2022: $801 · 2023: $420 · 2024: $207 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.32 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.99 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $179.90 | 2021-2023 | |
| Genzyme Corporation | $172.89 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.93 | 2021-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $151.25 | 2025 | Voquezna |
| Boston Scientific Corporation | $114.79 | 2022 | |
| Pfizer INC. | $84.68 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $83.50 | 2022 | |
| Ironwood Pharmaceuticals, INC | $78.71 | 2021-2022 | |
| Qol Medical, LLC | $65.95 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $46.74 | 2021-2022 | |
| Redhill Biopharma INC. | $34.85 | 2022 | |
| Madrigal Pharmaceuticals | $29.04 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $28.33 | 2023 | Terlivaz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $25.64 | 2025 | Zenpep |
| Ardelyx, INC. | $24.53 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $23.12 | 2021 | |
| Davol INC. | $16.69 | 2024 | Phasix Mesh |
| Daiichi Sankyo INC. | $15.50 | 2021 | |
| Axonics, INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukarram Amine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.